shivaani kummar ohsu email

Together their goal is to find a cure for cancer. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX 2022 ASCO Annual Meeting - Poster Session . (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. Support the Abortion Care and Training Fund. (h.c.), Ph.D., FAACR. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . Administrative Coordinator, Felicia Feingersch Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. Local: (503) 228-1730 | Toll Free: (800) 462-6608 Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. The couple says their ultimate goal is to develop new effective therapies for cancer. OHSU is an equal opportunity affirmative action institution. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Across OHSU, doctors and researchers are reimagining early disease detection. This center will be for the community, and we hope people will reach out to be a part of it. Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? Hamburger Menu x Home Dive into the research topics where Shivaani Kummar is active. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . 2001-2022 Oregon Health & Science University. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. massachusetts vs washington state. Cancer Early Detection Advanced Research Center, Adolescent and Young Adult Oncology Program, Social and Emotional Side Effects of Cancer, International Alliance for Early Cancer Detection (ACED), Lisa M. Coussens, M.D. Professor of Medicine, OHSU. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. . This philanthropy-fueled research revolution is already saving lives. Keep me signed in. Get to know some of the resear. You may also qualify for Phase 1 Program trials. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. what was bolivar's ultimate goal? Accueil; Solution; Tarif; PRO; Mon compte; France; Accueil; Solution For help with all referral needs and questions, visit Referring Physicians. My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . To find better ways to detect cancer. Bergan, R., Coussens, L., McWeeney, S., Spellman, P., Streeter, P., Winters-Stone, K., Bagby, G., Mori, M., Corless, C., Harrington, C., Hoatlin, M., Koop, D., Magun, B., Druker, B., Shannon, J. 23() 'Oregon Health & Science University Knight Cancer Institute(OHSU)' BAL0891 1 Shivaani Kummar (Principal Investigator, PI), OHSU 'Mary Crowley Cancer Research . OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, New England Journal of Medicine 378 (8), 731-739. The 13,000-square-foot early-phase research unit is located on the 12th floor of OHSUs Center for Health and Healing Building 2 on OHSUs South Waterfront campus. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography If you made any changes in Pure these will be visible here soon. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. The field of oncology is so broad, and theres so much to be done, Kummar says. What excites you about coming to work in the morning? Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. Claire Yoshida, M.S.N., A.C.N.S.-B.C., A.C.H.P.N. S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, Journal of Soil and Water Conservation 53 (3), 230-240. Trisha Silbernagel, RN, BSN, early-phase clinical trial unit manager, checks equipment on Aug. 23, 2021. The Division of Hematology and Medical Oncology is headed by Shivaani Kummar, M.D., FACP and composed of many sections: Classical Hematology Community Oncology Hematologic Malignancies Palliative Care Portland VA Research Solid Tumor Stem Cell Transplantation Administration Section head Shivaani Kummar, M.D., FACP Share on print. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. bard college music faculty. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. shivaani kummar ohsu email. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. However, high costs, long development t Accepting new patients Cited by. Overall: 4.7 out of 5 Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. Very few institutions do it well, but OHSU truly gets it, Kummar says. Email: trials@ohsu.edu Call: 503-494-1080 Abstracts & Presentations. Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Dr. Kummar specializes in the care and treatment of patients with cancer. NPI Lookup NPI Database. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Their partnership will be a perfect pairing.. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. . Vol.49 No.07. (h.c.), Ph.D., FAACR. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. Increasing patient participation in oncology clinical trials, A Novel Artificial IntelligencePowered Method for Prediction of Early Recurrence of Prostate Cancer after Prostatectomy and Cancer Drivers, Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas, Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer. Shivaani Kummar Director of Center for Experimental Therapeutics, Professor and Endowed Chair, Knight Cancer Institute mollie hemingway face shivaani kummar ohsu email. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. Dr. The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. Dr. Kummar loves to spend time with her family, read, and go for long walks. Clinical trials are research studies that test how well new medicines or treatments work in people. She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. At the end of the day, we need to develop better treatment for cancer patients and the only way to build that is through collaboration within OHSU and with other academic centers, biotech and pharma companies., Team science can be a buzz word. She accepts multiple insurance plans. Shivaani Kummar Aim: Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of. These topic labels come from the works of this person. Administrative Coordinator, Karri Garaventa Most recently, he was the director for Stanford SRI Drug Discovery and Development Program, and he trained with Nobel laureate Herb Brown at Purdue University. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP Caring for them drives me to work harder to develop more effective treatments that are better tolerated. Title. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Want to join the faculty at the Knight Cancer Institute? It is a privilege to be able to work in this field. Dr. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . Notice of Privacy Practices Where is Dr. Shivaani Kummar located? Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. Shivaani Kummar. Kummars remarkable accomplishments, combined with her ability to connect with people and her clear vision for how to grow the hematology-oncology division, made her our top candidate. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. PHYSICIAN HELPLINE Phone: 1-866-742-4811 Fax: 650-320-9443 Monday - Friday, 8 a.m. - 5 p.m. Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. . Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. 2001-2022 Oregon Health & Science University. Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone Password. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being.

Where Was The Rinvoq Commercial Filmed, Stopping Progesterone At 9 Weeks, Articles S